Pharmacokinetics of mirabegron, a β3-adrenoceptor agonist for treatment of overactive bladder, in healthy japanese male subjects: Results from single- and multiple-dose studies

Clinical Drug Investigation

Volumn 34, Issue 1, 2014, Pages 27-35

  Iitsuka, Hiromi ^a   Tokuno, Tomoaki ^a   Amada, Yoko ^a   Matsushima, Hiroshi ^a   Katashima, Masataka ^a   Sawamoto, Taiji ^a   Takusagawa, Shin ^a   Van Gelderen, Marcel ^b   Tanaka, Takanori ^c   Miyahara, Hideo ^d  

^a ASTELLAS PHARMA INC   (Japan)

^b Astellas Pharma Global Development   (Netherlands)

^c Medical Co LTA   (Japan)

^d TOYOHASHI SOZO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLASE; MIRABEGRON; PLACEBO; ACETANILIDE DERIVATIVE; ADRENERGIC RECEPTOR STIMULATING AGENT; THIAZOLE DERIVATIVE;

ADULT; AMYLASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EXCRETION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG TOLERABILITY; ELECTROCARDIOGRAM; HEART DISEASE; HEART PALPITATION; HEART RATE; HUMAN; HUMAN EXPERIMENT; JAPANESE; LABORATORY TEST; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; OVERACTIVE BLADDER; PARALLEL DESIGN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PULSE RATE; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; STEADY STATE; TABLET; URINALYSIS; VASCULAR DISEASE; ASIAN CONTINENTAL ANCESTRY GROUP; JAPAN; URINARY BLADDER, OVERACTIVE; YOUNG ADULT;

ACETANILIDES; ADRENERGIC AGONISTS; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; DOSE-RESPONSE RELATIONSHIP, DRUG; HEALTHY VOLUNTEERS; HUMANS; JAPAN; MALE; SINGLE-BLIND METHOD; THIAZOLES; URINARY BLADDER, OVERACTIVE; YOUNG ADULT;

EID: 84891860819     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-013-0146-1     Document Type: Article

References (21)

1. Takasu T, Ukai M, Sato S, et al. Effect of (R)-2-(2-aminothiazol-4-yl)- 4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective β3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther. 2007;321:642-7. (Pubitemid 46624504)
2. Yamaguchi O. β3-adrenoceptors in human detrusor muscle. Urology. 2002;59:25-9. (Pubitemid 34462255)
3. Yamaguchi O, Chapple CR. β3-adrenoceptors in urinary bladder. Neurourol Urodyn. 2007;26:752-6. (Pubitemid 47548235)
4. Astellas Pharma. Betanis tablets Japanese prescribing information. July 2011. http://www.info.pmda.go.jp/shinyaku/P201100119/80012600-22300AMX00592- A100-1.pdf. Accessed 29 Oct 2013
5. Astellas Pharma US Inc. Myrbetriq United States prescribing information. June 2012. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm? fuseaction=Search.Set-Current-Drug&ApplNo=202611&DrugName= MYRBETRIQ&ActiveIngred=MIRABEGRON&SponsorApplicant=APGDI& ProductMktStatus=1&goto=Search.Label-ApprovalHistory. Accessed 29 Oct 2013
6. Athanasopoulos A, Giannitsas K. An overview of the clinical use of antimuscarinics in the treatment of overactive bladder. Adv Urol. 2011;2011:820816
7. Eltink C, Lee J, Schaddelee M, et al. Single dose pharmacokinetics and absolute bioavailability of mirabegron, β3-adrenoceptor agonist for treatment of overactive bladder. Int J Clin Pharm Ther. 2012;50:838-49.
8. Krauwinkel W, Van Dijk J, Schaddelee M, et al. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women. Clin Ther. 2012;34:2144-60.
9. Takusagawa S, van Lier JJ, Suzuki K, et al. Absorption, metabolism and excretion of [14C]mirabegron (YM178), a potent and selective β3-adrenoceptor agonist, after oral administration to healthy male volunteers. Drug Metab Dispos. 2012;40:815-24.
10. Takusagawa S, Yajima K, Miyashita A, et al. Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective β3-adrenoceptor agonist. Xenobiotica. 2012;42:957-67.
11. van Gelderen E, Li Q, Meijer J, et al. An exploratory comparison of the single dose pharmacokinetics of the β3-adrenoceptor agonist mirabegron in healthy CYP2D6 poor and extensive metabolizers. Clin Pharmacol Ther. 2009;85(Suppl 1):S88.
12. Sawamoto T, Lee J, Alak A, et al. Phase I, open-label, drug interaction study to evaluate the effect of multiple doses of ketoconazole on single dose mirabegron (YM178) oral controlled absorption system (OCAS) in healthy adult subjects. Clin Pharmacol Ther 2011; 89(Suppl. 1):S21.
13. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Adopted by the 18th WMA General assembly and amended by 48th WMA General Assembly, Somerset West, South Africa, October 1996. http://www.wma.net/en/30publications/10policies/b3/. Accessed 29 Oct 2013.
14. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Guideline for good clinical practice E6(R1). http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/ Guidelines/Efficacy/E6-R1/Step4/E6-R1-Guideline.pdf. Accessed 31 July 2013
15. Chapple CR. The development of the oral controlled absorption system (Ocas®): a new improved formulation of tamsulosin. Eur Urol Suppl. 2005;4:1-4. (Pubitemid 41160472)
16. Van Teijlingen R, Meijer J, Takusagawa S, et al. Development and validation of LC-MS/MS methods for the determination of mirabegron and its metabolites in human plasma and their application to a clinical pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;887-888:102-11.
17. Gabrielsson J, Weiner D. Pharmacokinetic and pharmacodynamic data analysis: concepts and applications. 4th ed. Stockholm: Swedish Pharmaceutical Press; 2007.
18. Gough K, Hutchison M, Keene O, et al. Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry/pharmacokinetics UK joint working party. Drug Inf J. 1995;29:1039-48.
19. Smith BP, Vandenhende FR, DeSante KA, et al. Confidence interval criteria for assessment of dose proportionality. Pharm Res. 2000;17:1278-83.
20. Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and application. 3rd ed. Baltimore: Lippincott Williams & Wilkins; 1995.
21. Takusagawa S, Ushigome F, Nemoto H, et al. Intestinal absorption mechanism of mirabegron, a potent and selective β3-adrenoceptor agonist: involvement of human efflux and/or influx transport systems. Mol Pharm. 2013;10:1783-94.